



Surgery free delivery of Omnigen®

# Omnilenz®

Bandage contact lens application of amniotic membrane  
in a outpatient setting

## SUPPORTS NATURAL RECOVERY

- Facilitates natural healing and recovery
- Manages inflammation progression to provide an environment conducive for healing
- Physically alleviates pain

## SIMPLE 4 - 6 MINUTE PROCEDURE


- Removes costly theatre time
- Accessible in non-scheduled and emergency situations
- Earlier patient pathway intervention

## EARLY AND EFFECTIVE AMBULATORY INTERVENTION

- Barrier function of amniotic membrane delivered in an outpatient setting
- Reduces the need for surgical intervention
- Easier access to amniotic membrane transplantation


# Omnigen® - Amniotic Membrane

NuVision's proprietary Tereo® manufacture process delicately captures the native integrity, quality and structural composition of fresh amniotic membrane in a convenient dry and stable format. <sup>1,2</sup>



## What is the OmniLenz?

OmniLenz® is a bandage contact lens designed to apply Omnigen® to the ocular surface in a 4-6 minute procedure in an outpatient setting.




# Benefits of OmniLenz® application of Omnigen®

## Omnigen®- OmniLenz® AMT vs. Surgical patch-AMT v SoC

	Omnigen®-OmniLenz® AMT	Surgical patch-AMT	Standard of care (SoC)*
Non-scheduled and emergency ambulatory situations	✓	✗	✓
Improved time and cost efficiency	✓	✗	✓
Simple application	✓	✗	✓
Effective in refractory conditions	✓	✓	✗
Effective and efficient treatment pathway	✓	✗	✗

\*Standard of care (SoC): Medical management, BCL, Botox, Tarsorrhaphy



A) Patient 5 days following an alkali injury with a large area conjunctival and epithelial defect <sup>6</sup>



B) The patient 14 days following Omnigen-OmniLenz application with a fully healed ocular surface <sup>6</sup>

## Omnigen®- OmniLenz® Specifications

	<b>C-range</b>	<b>L-range</b>	<b>VIEW-range</b>
Omnigen diameter	12mm	17mm	17mm with 6mm aperture
OmniLenz diameter	16mm	18mm	18mm
OmniLenz base	Menicon 72	Definitive™ 74	Menicon 72
Water content	72%	74%	72%
Base curve	8.8	9.0	8.8 to 9.0
Oxygen permeability (Dk)	34	60	34
Oxygen Transmissibility (Dk/t)	23 (wet)	37.5 (wet)	23 (wet)

## OmniLenz® Patient Selection

OmniLenz® may not be compatible with patients with the following behavioural pathologies:

- Patients with abnormal blinking
- Patients unable to give consent for the treatment
- Patients prone to excessive rubbing of the eye
- Patients with an irregular topography of the ocular surface

## Regulatory

Omnigen® is aseptically processed according to the regulatory standards of the Human Tissue Authority (HTA) Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment. Traceability of Omnigen transplantations should always be noted.

Tissue decontamination is performed using an antibiotic-antimycotic solution. Traces of antibiotics will be present in the allograft. You should assess all patients for antibiotic sensitivity before treatment.

<b>Omnigen® is aseptically processed and tested for the following prior to release following Annex B of the HTA Guide to Quality and Safety Assurance for Human Tissues and Cells for Patient Treatment (Directions 001/2021)</b>	<b>HIV: Anti HIV1, HIV2 &amp; p24</b>
	<b>HIV-1 RNA Viral Load</b>
	<b>Hepatitis B: HBsAg &amp; anti-HBc</b>
	<b>Hepatitis B Virus DNA</b>
	<b>Hepatitis C: Anti-HCV-Ab</b>
	<b>Hepatitis C Virus RNA</b>
	<b>Syphilis: IgG/IgM &amp; RPR</b>
	<b>Hepatitis E Virus RNA</b>
	<b>HTLV-I/II Antibody</b>
	<b>Cytomegalovirus</b>

**OmniLenz® is manufactured by Menicon Ltd.**

Refer to Menicon Ltd Soft Contact Lens IFU for guidance on wear. The eyecare practitioner is responsible for detailing a lens wearing schedule and the period of wear.

## Contact

Get in touch with the NuVision team to learn more about Omnigen and to explore how it may benefit your clinical service.

**NuVision Biotherapies**

**Email: [info@nu-vision.co.uk](mailto:info@nu-vision.co.uk)**

**Website: [www.nu-vision.co.uk](http://www.nu-vision.co.uk)**

## References

1. Allen CL, *et al.* Augmented dried versus cryopreserved amniotic membrane as an ocular surface dressing. PloS one 2013; 8(10): e78441.
2. Marsit NM, *et al.* Validation and assessment of an antibiotic-based, aseptic decontamination manufacturing protocol for therapeutic, vacuum-dried human amniotic membrane. Scientific Reports 2019; 9(1): 12854.
3. Walkden A. Amniotic Membrane Transplantation in Ophthalmology: An Updated Perspective. Clin Ophthalmol 2020; 14: 2057-2072.
4. Rock T, *et al.* Amniotic Membrane Transplantation in Reconstructive and Regenerative Ophthalmology. Ann Transplant 2018; 23: 160-165.
5. Kim JS, *et al.* Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp Eye Res 2000; 70(3): 329-337.
6. V-Q08 NuVision Internal Case Study